Bosh sahifaNSIS-B • CPH
add
Novozymes A/S
Yopilish kursi
410,00 kr
Kunlik diapazon
410,70 kr - 429,40 kr
Yillik diapazon
375,90 kr - 485,90 kr
Bozor kapitalizatsiyasi
176,44 mlrd DKK
Oʻrtacha hajm
520,30 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
CPH
Bozor yangiliklari
MarketWatch
1 kun oldin
S&P 500 is on a 12-month tear as tariffs threaten 2025 outlook for U.S.
stocks
1,12%
0,35%
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (EUR) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 915,85 mln | 61,70% |
Joriy xarajat | 271,75 mln | 52,62% |
Sof foyda | 31,95 mln | -60,72% |
Sof foyda marjasi | 3,49 | -75,70% |
Har bir ulushga tushum | — | — |
EBITDA | 150,94 mln | -16,50% |
Amaldagi soliq stavkasi | 29,00% | — |
Balans
Jami aktivlari
Jami passivlari
| (EUR) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 260,80 mln | 85,35% |
Jami aktivlari | 15,25 mlrd | 302,43% |
Jami passivlari | 4,25 mlrd | 119,23% |
Umumiy kapital | 11,00 mlrd | — |
Tarqatilgan aksiyalar | 277,90 mln | — |
Narxi/balansdagi bahosi | 10,35 | — |
Aktivlardan daromad | 1,83% | — |
Kapitaldan daromad | 2,15% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (EUR) | iyn, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 31,95 mln | -60,72% |
Operatsiyalardan naqd pul | 264,05 mln | 74,01% |
Sarmoyadan naqd pul | -27,45 mln | 70,98% |
Moliyadan naqd pul | -186,70 mln | -205,10% |
Naqd pulning sof oʻzgarishi | 55,55 mln | 902,56% |
Boʻsh pul | -17,57 mln | 68,87% |
Haqida
Novozymes A/S was a global biotechnology company headquartered in Bagsværd, outside of Copenhagen, Denmark. The company's focus was the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company merged with Chr. Hansen to form Novonesis in January 2024.
Prior to the merger, the company had operations around the world, including in China, India, Brazil, Argentina, United Kingdom, the United States, and Canada. Class B shares of its stock were listed on the NASDAQ OMX Nordic exchange.
On 12 December 2023, it was announced that Novozymes and Danish bioscience company Chr. Hansen had obtained regulatory approval for a merger, and on the following day, the name of the combined company was revealed as Novonesis. Wikipedia
CEO
Tashkil etilgan
2000
Sayt
Xodimlar soni
10 452
